PD-L1 monoclonal antibody combined with SBRT brings new neoadjuvant treatment options for early resectable NSCLC, especially for stage IIIA patients; its benefits in stage I–II NSCLC may redefine the applicability of neoadjuvant therapy patient. Here, CD274 is linked to non-small cell lung carcinoma.